WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 11, 723-728. Research Article ISSN 2277–7105

ARTIFICIAL INTELLIGENCE DRIVEN PHARMACOVIGILANCE INNOVATION IN DRUG SAFETY

Rathore Vivek Singh*, Sawner Yashraj, Dawar Sachin, Jaiswal Manoj

Charak Institute of Pharmacy, Choli Road Mandleshwar.

Article Received on 30 April 2026,
Article Revised on 20 May 2026,
Article Published on 01 June 2026,

https://doi.org/10.5281/zenodo.20440330

***Corresponding Author**

Rathore Vivek Singh

Charak Institute of Pharmacy, Choli Road Mandleshwar.

How to cite this Article: Rathore Vivek Singh*, Sawner Yashraj, Dawar Sachin, Jaiswal Manoj. (2026). Artificial Intelligence Driven Pharmacovigilance Innovation In Drug Safety. World Journal of Pharmaceutical Research, 15(11), 723–728.

ABSTRACT

Artificial Intelligence (AI)-driven pharmacovigilance is transforming drug safety by enhancing the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs). Traditional pharmacovigilance systems often rely on manual reporting processes, which are time-consuming, resource-intensive, and limited by underreporting and delayed signal detection. This paper explores the integration of advanced AI technologies—including machine learning (ML), natural language processing (NLP), deep learning, and big data analytics—into pharmacovigilance frameworks to improve efficiency, accuracy, and real-time monitoring of drug safety. AI-powered systems can analyze vast volumes of structured and unstructured healthcare data from sources such as electronic health records (EHRs), social media, clinical trial reports, and spontaneous reporting systems to identify safety signals more rapidly than conventional methods. The study highlights key innovations, including automated case processing, predictive risk modeling, duplicate detection, and signal prioritization, while also examining regulatory considerations and implementation challenges such as data privacy, algorithm transparency, and validation requirements.

KEYWORDS: Artificial Intelligence (AI), Pharmacovigilance, Drug Safety, Adverse Drug Reactions (ADRs), Machine Learning, Natural Language Processing (NLP), Signal Detection, Big Data Analytics, Drug Safety Monitoring, Healthcare Innovation.

1. INTRODUCTION

Pharmacovigilance, the science of monitoring and assessing the safety of pharmaceuticals, plays a critical role in ensuring patient well-being and public health. Central to pharmacovigilance is signal detection, the process of identifying potential adverse drug reactions (ADRs) and safety concerns associated with medications. Traditionally, signal detection relied heavily on manual methods and retrospective analyses of adverse event reports, leading to limitations in scalability, timeliness, and accuracy. However, the landscape of pharmacovigilance has been revolutionized by the integration of artificial intelligence (AI) technologies. AI-driven signal detection represents a paradigm shift, offering unprecedented capabilities to analyze vast amounts of structured and unstructured data in near real-time. Machine learning algorithms, natural language processing techniques, and data mining approaches have emerged as powerful tools in identifying hidden patterns, correlations, and emerging safety signals within pharmacovigilance data. This review paper aims to explore the advancements, challenges, and future directions of AI-driven signal detection in pharmacovigilance. We will delve into the transformative impact of AI technologies on signal detection methodologies, discussing their role in enhancing drug safety surveillance, risk management, and regulatory compliance.

2. METHOD

The selected literature focused on AI technologies such as machine learning (ML), deep learning, natural language processing (NLP), robotic process automation (RPA), and big data analytics applied to pharmacovigilance processes. Data from published case studies, regulatory frameworks, and industry reports were systematically analyzed to compare traditional pharmacovigilance methods with AI-driven approaches.

The methodology further examined major AI applications including

- Automated adverse event case intake and processing
- Signal detection and risk identification
- Duplicate report detection
- Social media and electronic health record data mining
- Predictive safety analytics

Comparative performance analysis was conducted based on parameters such as speed, accuracy, scalability, cost-effectiveness, and regulatory compliance. Challenges related to

data privacy, ethical concerns, model transparency, and implementation barriers were also assessed. This research used qualitative synthesis and comparative analysis to generate insights into the effectiveness of AI-driven pharmacovigilance systems.

3. EVALUATION PARAMETER

Evaluation of AI models in pharmacovigilance must consider both technical and clinical relevance:

Advanced Evaluation Metrics for Pharmacovigilance

3.1 Signal Detection Accuracy

- Measures correctness of detected drug-event signals
- Compared against validated safety signals

3.2 Time-to-Signal Detection

- Critical metric in PV
- AI reduces detection time significantly compared to traditional systems

3.3 False Signal Rate

- Frequency of incorrect safety signals
- Important to minimize regulatory burden

3.4 Case Processing Efficiency

- Number of cases processed per unit time
- Reduction in manual workload

3.5 Handling Imbalanced Data in PV Evaluation

Pharmacovigilance datasets are highly imbalanced (few ADRs vs many non-ADRs). Challenges:

- Biased model predictions
- Misleading accuracy Solutions:
- Oversampling (SMOTE)
- Undersampling
- Cost-sensitive learning

3.6 Cross-Validation

- K-fold cross-validation ensures model robustness

a. External Validation

- Testing on independent datasets
- Ensures generalizability 3.7Temporal Validation
- Evaluates model performance over time
- Critical for real-world PV systems

3.8 Real-World Validation

- Deployment in hospital or regulatory systems
- Continuous monitoring of performance

3.9 Confusion Matrix

Provides detailed breakdown:

- True Positives (TP)
- False Positives (FP)
- True Negatives (TN)
- False Negatives (FN)

3.10 Model Interpretability Tools

- SHAP (Shapley Additive Explanations)
- LIME (Local Interpretable Model-Agnostic Explanations)
- These tools enhance trust and regulatory acceptance.

3.11 Regulatory Evaluation Considerations Agencies such as

- World Health Organization
- U.S. Food and Drug Administration
- Transparent validation processes
- Reproducibility of results
- Continuous performance monitoring
- Quantitative Metrics.
- Accuracy, Precision, Recall, F1-score

4. RESULT AND DISCUSSION

AI-based pharmacovigilance systems have shown substantial improvements in automated case processing through NLP-driven extraction of relevant safety information from medical literature, spontaneous reports, social media platforms, and electronic health records. This automation reduces human workload, minimizes reporting delays, and increases operational productivity. Furthermore, predictive analytics models have strengthened proactive safety surveillance by forecasting potential drug-related risks before they escalate into widespread public health issues. Duplicate report detection systems powered by AI have also improved data accuracy and database integrity, ensuring more reliable safety evaluations.

Comparative assessments indicate that AI-driven pharmacovigilance offers notable advantages over traditional systems, including faster processing times, improved scalabilit y, enhanced data mining efficiency, and reduced operational costs. These benefits position AI as a powerful tool for supporting regulatory agencies and pharmaceutical companies in maintaining comprehensive drug safety oversight.

5. SUMMARY AND CONCLUSION

Artificial Intelligence (AI) has emerged as a transformative force in the field of pharmacovigilance, significantly enhancing the detection, assessment, and prevention of adverse drug reactions (ADRs). This study explored the integration of AI technologies—such as machine learning, natural language processing (NLP), and deep learning—into traditional pharmacovigilance systems to improve drug safety monitoring.

The findings of this thesis confirm that AI-driven pharmacovigilance represents a paradigm shift in drug safety management. The integration of intelligent systems into pharmacovigilance workflows enhances efficiency, accuracy, and timeliness, ultimately contributing to improved patient safety outcomes.

6. REFERENCES

1. Chavhan, A. R., & Uplenchwar, P. M. AI-Driven Signal Detection in Pharmacovigilance: Advancements, Challenges, and Future Directions. Human Journals – International Journal of Pharmaceutical and Phytopharmacological Research, 2024; 30(5): 99– 119.
2. Kumar, R. K. S., & Velusamy, S. Harnessing Artificial Intelligence for Enhanced Pharmacovigilance: A Comprehensive Review. Indian Journal of Pharmacy Practice, 2025; 18(2): 171–179.

3. Shinde, S. S., Dharanguttikar, V. R., Shinde, P. S., Shitole, P. D., & Ghare, K. B. Use of artificial intelligence in pharmacovigilance – A systematic review. International Journal of Novel Research and Development, 2025; 10(4): 701–716.
4. Archana, M., Mukherjee, S., Johny, G. A., Jagadeesh, E., & Vengadesan, S. Artificial Intelligence - Driven Pharmacovigilance in Resource-Limited Settings. International Journal of Trend in Scientific Research and Development, 2024; 8(4): 593–599.
5. Singh, P., Vaishnav, Y., & Verma, S. Development of pharmacovigilance system in India and paradigm of pharmacovigilance research: An overview. Current Drug Safety, 2023; 18: 448-464.
6. Wasiullah, M., Yadav, P., Yadav, S. K., & Chauhan, R. Artificial intelligence in pharmacovigilance: Improving drug safety. Research & Reviews: Journal of Computational Biology, 2025; 14(1): 101-118.
7. Nilsen, P. Making sense of implementation theories, models and frameworks. Implementation Science, 2015; 10(1): 53.
8. Yu, K.-H., Beam, A. L., & Kohane, I. S. Artificial intelligence in healthcare. Nature Biomedical Engineering, 2018; 2: 719-731.
9. Singh, P., Vaishnav, Y., & Verma, S. Development of pharmacovigilance system in India and paradigm of pharmacovigilance research: An overview. Current Drug Safety, 2023; 18: 448-464.
10. Wasiullah, M., Yadav, P., Yadav, S. K., & Chauhan, R. Artificial intelligence in pharmacovigilance: Improving drug safety. Research & Reviews: Journal of Computational Biology, 2025; 14(1): 101-118.